Lynch syndrome genes

被引:203
作者
Peltomäki, P [1 ]
机构
[1] Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, FIN-00014 Helsinki, Finland
关键词
hereditary nonpolyposis colorectal cancer; MLH1; MLH3; MSH2; MSH6; PMS2;
D O I
10.1007/s10689-004-7993-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the discovery of the major human genes with DNA mismatch repair (MMR) function in 1993-1995, mutations in four, MSH2, MLH1, MSH6, and PMS2, have been convincingly linked to susceptibility of hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Among these, PMS2 mutations are associated with diverse clinical features, including those of the Turcot syndrome. Two additional MMR genes, MLH3 and PMS1, have also been proposed to play a role in Lynch syndrome predisposition, but the clinical significance of mutations in these genes is less clear. According to the database maintained by the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC), current InSiGHT (International Society for Gastrointestinal Hereditary Tumors), approximately 500 different HNPCC-associated MMR gene mutations are known that primarily involve MLH1 (similar to 50%), MSH2 (similar to 40%), and MSH6 (similar to 10%). Examination of HNPCC/Lynch syndrome-associated MMR genes and their mutations has revealed several other important functions for their protein products beyond postreplicative mismatch repair as well as many alternative mechanisms of pathogenicity. Despite these advances, much is yet to be learned about the molecular basis of correlations between genetic changes and clinical features of the disease.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 87 条
[61]   Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression [J].
Plaschke, J ;
Krüger, S ;
Jeske, B ;
Theissig, F ;
Kreuz, FR ;
Pistorius, S ;
Saeger, HD ;
Iaccarino, I ;
Marra, G ;
Schackert, HK .
CANCER RESEARCH, 2004, 64 (03) :864-870
[62]   Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation [J].
Plaschke, J ;
Krüger, S ;
Pistorius, S ;
Theissig, F ;
Saeger, HD ;
Schackert, HK .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) :643-648
[63]  
Plaschke J, 2000, INT J CANCER, V85, P606, DOI 10.1002/(SICI)1097-0215(20000301)85:5<606::AID-IJC2>3.0.CO
[64]  
2-B
[65]   Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair [J].
Prolla, TA ;
Baker, SM ;
Harris, AC ;
Tsao, EL ;
Yao, X ;
Bronner, CE ;
Zheng, BH ;
Gordon, M ;
Reneker, J ;
Arnheim, N ;
Shibata, D ;
Bradley, A ;
Liskay, RM .
NATURE GENETICS, 1998, 18 (03) :276-279
[66]   Pathogenicity of the hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the functional protein [J].
Raevaara, TE ;
Vaccaro, C ;
Abdel-Rahman, WM ;
Mocetti, E ;
Bala, S ;
Lönnqvist, KE ;
Kariola, R ;
Lynch, HT ;
Peltomäki, P ;
Nyström-Lahti, M .
GASTROENTEROLOGY, 2003, 125 (02) :501-509
[67]   Identification of hMutLβ, a heterodimer of hMLH1 and hPMS1 [J].
Räschle, M ;
Marra, G ;
Nyström-Lahti, M ;
Schär, P ;
Jiricny, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32368-32375
[68]  
Risinger JI, 1998, CANCER RES, V58, P2978
[69]  
Schmutte C, 1998, CANCER RES, V58, P5023
[70]  
Schweizer P, 2001, CANCER RES, V61, P2813